| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
University Department of Medicine, Western Australian Institute for Medical Research, Queen Elizabeth II Medical Centre, Nedlands, Perth, Western Australia 6009
Cytotoxic chemotherapy is generally considered immunosuppressive, with neutropenia and lymphopenia being common adverse side effects. In this context, we have shown previously that the cytidine analogue, gemcitabine, abolishes humoral responses but, in contrast, augments antigen-specific cellular antitumor immunity. This augmentation occurs in the context of increased antigen cross-presentation, T lymphocyte expansion, and infiltration of the tumor. Here, we combine an immunotherapy (CD40 ligation using FGK45; 100 µg; i.p., q2dx3) with gemcitabine (120 µg/gram; i.p.; q3dx5) to treat established solid tumors. This protocol induced long-term cures in 
80% of mice, and all of the cured mice were resistant to tumor rechallenge. Synergy between the drug and immunotherapy could not be established in vitro and was only seen in the context of tumor cell death. It was associated with an increase in both CD4 and CD8 T-cell infiltration of the tumor, but depletion studies clearly showed that CD4 T cells were not a necessary component of the cure. In contrast, CD8 T cells were absolutely required for the success of this treatment regimen. The priming effect of gemcitabine was not limited to debulking, because mice resected to an equivalent, or lesser residual tumor volume did not eradicate tumor with subsequent immunotherapy. This study provides evidence that chemotherapy has the capacity to augment cellular antitumor immunity, a finding with wider implications for the management of treatment-resistant solid tumors.
This article has been cited by other articles:
|
|
 |
|
  L. de la Cruz-Merino, E. Grande-Pulido, A. Albero-Tamarit, and M. E. Codes-Manuel de Villena Cancer and Immune Response: Old and New Evidence for Future Challenges Oncologist, December 1, 2008; 13(12): 1246 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jackaman, A. M. Lew, Y. Zhan, J. E. Allan, B. Koloska, P. T. Graham, B. W. S. Robinson, and D. J. Nelson Deliberately provoking local inflammation drives tumors to become their own protective vaccine site Int. Immunol., November 1, 2008; 20(11): 1467 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Kim, B. K. Choi, K. H. Kim, S. W. Kang, and B. S. Kwon Combination Therapy with Cisplatin and Anti-4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced Nephrotoxicity Cancer Res., September 15, 2008; 68(18): 7264 - 7269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. De Vleeschouwer, S. Fieuws, S. Rutkowski, F. Van Calenbergh, J. Van Loon, J. Goffin, R. Sciot, G. Wilms, P. Demaerel, M. Warmuth-Metz, et al. Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme Clin. Cancer Res., May 15, 2008; 14(10): 3098 - 3104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Morris, C. Platell, and B. Iacopetta Tumor-Infiltrating Lymphocytes and Perforation in Colon Cancer Predict Positive Response to 5-Fluorouracil Chemotherapy Clin. Cancer Res., March 1, 2008; 14(5): 1413 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, L. Xiang, R. Hassan, and I. Pastan Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors PNAS, October 23, 2007; 104(43): 17099 - 17104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhong, B. Han, I. L. Tourkova, A. Lokshin, A. Rosenbloom, M. R. Shurin, and G. V. Shurin Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth Clin. Cancer Res., September 15, 2007; 13(18): 5455 - 5462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Bauer, F Bauernfeind, A Sterzik, M Orban, M Schnurr, H A Lehr, S Endres, A Eigler, and M Dauer Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut, September 1, 2007; 56(9): 1275 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Wall, K. Milne, M. L. Martin, P. H. Watson, P. Theiss, and B. H. Nelson Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells Cancer Res., July 1, 2007; 67(13): 6442 - 6450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Manning, J. G.M. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism Clin. Cancer Res., July 1, 2007; 13(13): 3951 - 3959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Vonderheide Prospect of Targeting the CD40 Pathway for Cancer Therapy Clin. Cancer Res., February 15, 2007; 13(4): 1083 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gamrekelashvili, C. Kruger, R. von Wasielewski, M. Hoffmann, K. M. Huster, D. H. Busch, M. P. Manns, F. Korangy, and T. F. Greten Necrotic Tumor Cell Death In Vivo Impairs Tumor-Specific Immune Responses J. Immunol., February 1, 2007; 178(3): 1573 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Kang, J. H. Lee, C. K. Song, H. D. Han, B. C. Shin, S. I. Pai, C.-F. Hung, C. Trimble, J.-S. Lim, T. W. Kim, et al. Epigallocatechin-3-Gallate Enhances CD8+ T Cell-Mediated Antitumor Immunity Induced by DNA Vaccination Cancer Res., January 15, 2007; 67(2): 802 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H.M.G.M. den Brok, R. P.M. Sutmuller, S. Nierkens, E. J. Bennink, L. W.J. Toonen, C. G. Figdor, T. J.M. Ruers, and G. J. Adema Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine. Cancer Res., July 15, 2006; 66(14): 7285 - 7292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth, Y. Hayakawa, E. Cretney, N. Zerafa, P. Sivakumar, H. Yagita, and K. Takeda IL-21 Enhances Tumor-Specific CTL Induction by Anti-DR5 Antibody Therapy J. Immunol., May 15, 2006; 176(10): 6347 - 6355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. van der Most, A. Currie, B. W.S. Robinson, and R. A. Lake Cranking the Immunologic Engine with Chemotherapy: Using Context to Drive Tumor Antigen Cross-Presentation towards Useful Antitumor Immunity Cancer Res., January 15, 2006; 66(2): 601 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Correale, M. G. Cusi, K. Y. Tsang, M. T. Del Vecchio, S. Marsili, M. L. Placa, C. Intrivici, A. Aquino, L. Micheli, C. Nencini, et al. Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients J. Clin. Oncol., December 10, 2005; 23(35): 8950 - 8958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Robinson and R. A. Lake Advances in malignant mesothelioma. N. Engl. J. Med., October 13, 2005; 353(15): 1591 - 1603. [Full Text] [PDF]
|
|
|
|
|
|
S. Broomfield, A. Currie, R. G. van der Most, M. Brown, I. van Bruggen, B. W.S. Robinson, and R. A. Lake Partial, but not Complete, Tumor-Debulking Surgery Promotes Protective Antitumor Memory when Combined with Chemotherapy and Adjuvant Immunotherapy Cancer Res., September 1, 2005; 65(17): 7580 - 7584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Correale*, M. G. Cusi, M. T. Del Vecchio, A. Aquino, S. Prete, K. Y. Tsang, L. Micheli, C. Nencini, M. La Placa*, F. Montagnani*, et al. Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro J. Immunol., July 15, 2005; 175(2): 820 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Casati, V. S. Zimmermann, F. Benigni, M. T. S. Bertilaccio, M. Bellone, and A. Mondino The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration J. Immunol., March 15, 2005; 174(6): 3317 - 3325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. D. van Mierlo, Z. F. H. M. Boonman, H. M. H. Dumortier, A. Th. den Boer, M. F. Fransen, J. Nouta, E. I. H. van der Voort, R. Offringa, R. E. M. Toes, and C. J. M. Melief Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication J. Immunol., December 1, 2004; 173(11): 6753 - 6759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Suzuki, V. Kapoor, H.-K. Cheung, L. E. Ling, P. A. DeLong, L. R. Kaiser, and S. M. Albelda Soluble Type II Transforming Growth Factor-{beta} Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity Clin. Cancer Res., September 1, 2004; 10(17): 5907 - 5918. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
